Health Tips for Hair Loss, Lyme Disease and More
August 13, 2020
Plus, Go Behind the Mystery of a Rare Genetic Disorder
Today on The Balancing Act, we examine health issues and solutions for a variety of conditions and ailments.
First, we go Behind the Mystery of a rare disease, fibrodysplasia ossificans progressive, or FOP for short. One of the rarest and most disabling genetic conditions known to medicine, FOP occurs when bone forms in muscles, tendons, ligaments, and other connective tissues. We meet Nancy, a courageous patient who has lived with FOP for 60 years. Today, FOP affects every joint in her body, except most of her fingers. At this time, there is no treatment for FOP, and the disorder will only worsen as the body continues to form new bone.
Next, we explore how to treat hair loss. From the causes, symptoms to preventative measures, scalp care and diet, many factors are involved in hair loss. Up to 40% of women experience some type of hair loss or alopecia—it’s not just an issue for men. Haircare expert Glenice Beale introduces Nioxin, a range of products designed to strengthen, nourish and repair thinning hair from the scalp, its foundation. Additionally, Brittany Cocilova shares her personal experience with hair thinning and the results she experienced while using Nioxin.
Finally, we look at Lyme Disease, an ailment that affects almost 400,000 Americans each year, a number that’s on the rise. Early detection and treatment can help resolve symptoms and prevent progression of Lyme disease. There is now a more timely solution for diagnosis. Sofia 2 Lyme FIA is the only CLIA-waived tier one Lyme test in the market.
Bringing the best tips from the experts in Atlanta in business, beauty, wealth management, child healthcare, car shopping, and more. Each year, Atlanta’s Women’s Entrepreneurship Initiative selects 15 local female entrepreneurs for a 15-month business training program. We meet women who have grown their companies, created jobs, and broke through the glass ceiling. With some […]
iMCD is the deadliest subtype of Castleman disease. Approximately one third of patients die within five years of diagnosis, and another third die within 10 years if not treated.
There are no effective treatment options for people with unresectable or metastatic chondrosarcoma despite many attempts by multiple pharmaceutical companies over the past few decades.